Stay updated with breaking news from Foundationone Liquid. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
New discoveries of specific biomarkers related to various cancer types are increasing researchers' trust in multicancer sequencing. FREMONT, Calif., April 28, 2023 /PRNewswire/ -- BIS Research
MedTech industry news
FoundationOne Liquid CDx, a liquid biopsy test, is the only blood-based CDx approved for the targeted cancer therapy.
The FoundationOne Liquid CDx test can be used with Tarceva (erlotinib), Tagrisso (osimertinib), and Iressa (gefitinib), and other TKIs approved in the future.
The FoundationOne Liquid CDx test can be used with Tarceva (erlotinib), Tagrisso (osimertinib), and Iressa (gefitinib), and other TKIs approved in the future.